Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II) - PubMed (original) (raw)

Randomized Controlled Trial

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II)

D S H Bell et al. Diabetes Obes Metab. 2011 Sep.

Abstract

Aim: To compare the efficacy of a fixed-dose triple oral diabetes polypill containing 1 or 2 mg glimepiride, 500 mg sustained-release metformin, and 15 mg pioglitazone (GMP) administered once daily with human insulin 70/30 mix and 500 mg sustained-release metformin administered twice daily (IM) in insulin-naÏve subjects with type 2 diabetes mellitus inadequately controlled [haemoglobin A1c (HbA1c) over 8.0%] on a combination of glimepiride and metformin.

Methods: One hundred and one subjects were randomized to GMP or IM regimens for 12 weeks. The primary outcome was the change in HbA1c and secondary outcomes were changes in fasting plasma, and postprandial plasma glucoses and the number of patients achieving a drop in HbA1c of over 1%. Other secondary outcomes were changes in the lipid profile, C-peptide level, body weight as well as physician assessments of efficacy and patient assessment of tolerability.

Results: The primary outcome of a change in HbA1c showed a trend towards a lower HbA1c with GMP therapy (-1.33% vs. -0.83%; p = 0.059). The number of subjects achieving a decrease in HbA1c of greater than 1.0% was significantly greater in the GMP therapy (72.5% vs. 22%; p = 0.0001). Both regimens equally and significantly reduced fasting and postprandial glucose levels (p = 0.05). Weight gain was nonsignificantly greater with IM (2.69 vs. 0.92 kg; p = 0.223). Investigator assessment of efficacy was significantly better with GMP (p = 0.001) as was tolerability as assessed by patients (p = 0.0001).

Conclusion: When compared with suboptimally titrated IM there was a trend towards a lower HbA1c with GMP and significantly more GMP subjects obtained an HbA1c under 7%. Global assessments by investigators and subjects showed both a greater efficacy and tolerability with GMP.

PubMed Disclaimer

Cited by

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. Blonde L, et al. Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11. Endocr Pract. 2022. PMID: 35963508 Free PMC article.
Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel.
Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, Shah P, Bajaj S, Deshmukh V, Sanyal D, Chandrasekaran S, Khandelwal D, Joshi A, Nair T, Eliana F, Permana H, Fariduddin MD, Shrestha PK, Shrestha D, Kahandawa S, Sumanathilaka M, Shaheed A, Rahim AA, Orabi A, Al-Ani A, Hussein W, Kumar D, Shaikh K. Kalra S, et al. J Family Med Prim Care. 2020 Nov 30;9(11):5450-5457. doi: 10.4103/jfmpc.jfmpc_843_20. eCollection 2020 Nov. J Family Med Prim Care. 2020. PMID: 33532378 Free PMC article. Review.
Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India.
Evans V, Roderick P, Pollock AM. Evans V, et al. BMJ Glob Health. 2018 Mar 6;3(2):e000263. doi: 10.1136/bmjgh-2016-000263. eCollection 2018. BMJ Glob Health. 2018. PMID: 29527355 Free PMC article. Review.
Therapeutic Targets for Management of Periodontitis and Diabetes.
Sima C, Van Dyke TE. Sima C, et al. Curr Pharm Des. 2016;22(15):2216-37. doi: 10.2174/1381612822666160216150338. Curr Pharm Des. 2016. PMID: 26881443 Free PMC article. Review.
The treatment of type 2 diabetes.
Pfeiffer AF, Klein HH. Pfeiffer AF, et al. Dtsch Arztebl Int. 2014 Jan 31;111(5):69-81; quiz 82. doi: 10.3238/arztebl.2014.0069. Dtsch Arztebl Int. 2014. PMID: 24612534 Free PMC article. Review.

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II) - PubMed (original) (raw)